Physician profile
Malathi V Koli
NPI 1447449889
$1,694.04
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $766 · 2021: $249.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $519.92 | 2019-2021 | |
| Allergan, INC. | $493.12 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $174.62 | 2019-2021 | |
| Lundbeck LLC | $173.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $124.67 | 2019 | |
| Bausch Health US, LLC | $65.30 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $43.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.30 | 2020 | |
| Abbvie INC. | $36.40 | 2021 | |
| Neuronetics, INC. | $11.60 | 2020 | |
| Upsher-Smith Laboratories LLC | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malathi Koli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.